Generic Name: loxapine
Brand Names:
Loxitane C, Loxitane
Special Alerts:
[Posted 02/22/2011] ISSUE: FDA notified healthcare professionals that the Pregnancy section of drug labels for the entire class of antipsychotic drugs has been updated. The new drug labels now contain more and consistent information about the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy.
The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding. In some newborns, the symptoms subside within hours or days and do not require specific treatment; other newborns may require longer hospital stays.
BACKGROUND: Antipsychotic drugs are used to treat symptoms of psychiatric disorders such as schizophrenia and bipolar disorder.
RECOMMENDATION: Healthcare professionals should be aware of the effects of antipsychotic medications on newborns when the medications are used during pregnancy. Patients should not stop taking these medications if they become pregnant without talking to their healthcare professional, as abruptly stopping antipsychotic medications can cause significant complications for treatment. For more information visit the FDA website at: [Web] and [Web].
[Posted 06/16/2008] FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. In April 2005, FDA notified healthcare professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, FDA has reviewed additional information that indicates the risk is also associated with conventional antipsychotics. Antipsychotics are not indicated for the treatment of dementia-related psychosis. The prescribing information for all antipsychotic drugs will now include the same information about this risk in a BOXED WARNING and the WARNINGS section. For more information visit the FDA website at: [Web], [Web] and [Web].
 | Watson 371 25 mg 25 mg
bottle, 100 each Loxapine Succ 25mg, Oral capsule, green, white, oblong-shaped, side 1:Watson 371 25 mg |
 | WATSON 372 50 mg 50 mg
bottle, 100 each Loxapine Succ 50mg, Oral capsule, blue, white, oblong-shaped, side 1:WATSON 372 50 mg |
 | Watson 370 10 mg 10 mg
bottle, 100 each Loxapine Succ 10mg, Oral capsule, white, yellow, oblong-shaped, side 1:Watson 370 10 mg |
 | MYLAN 7050 MYLAN 7050 50 mg
bottle, 100 each Loxapine Succ 50mg, Oral capsule, blue, green, oblong-shaped, side 1:MYLAN 7050 MYLAN 7050 |
 | WATSON 389 5 mg 5 mg
bottle, 100 each Loxapine Succ 5mg, Oral capsule, white, oblong-shaped, side 1:WATSON 389 5 mg |
 | Watson 369 5mg 5 mg
bottle, 100 each Loxapine Succ 5mg, Oral capsule, white, oblong-shaped, side 1:Watson 369 5mg |
The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks,
and other material contained on the Healthline Site ("Content"), its services, and any information or material
posted on the Healthline Site by third parties are provided for informational purposes only. None of the
foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek
the advice of a physician or other qualified healthcare provider with any questions you may have regarding a
medical condition. Never disregard professional medical advice or delay in seeking it because of something you
have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately.
Please read the
Terms of Service
for more information regarding use of the Healthline Site.
